Navigation Links
UNC-Chapel Hill, Hamner Institutes Announce Partnership to Accelerate Basic, Translational Research

RESEARCH TRIANGLE PARK, N.C., April 18 /PRNewswire/ -- The University of North Carolina at Chapel Hill and The Hamner Institutes for Health Sciences have signed a memorandum of understanding that will guide innovative collaborations in basic and translational research.

Established with Carolina's schools of medicine, pharmacy and public health, and its Kenan-Flagler Business School, this unique partnership capitalizes on the scientific strengths of a leading university and an independent research institute, both of which are committed to accelerating advances in human therapeutics and public health locally and internationally. Key initial areas of anticipated collaboration include pursuit of new therapies for cancer and respiratory diseases by advancing experimental and computational sciences in drug safety assessment, drug disposition, pharmacogenomics, genomic medicine, nanomedicine, drug delivery and public health.

The scientific and business-development teams at The Hamner Institutes will work with Carolina faculty, including those from the Center for Integrative Chemical Biology and Drug Discovery in the Schools of Pharmacy, Medicine and College of Arts and Sciences, UNC Kenan-Flagler Business School and the University's Office of Technology Development to identify, assess and enhance development of new research leads. Together, they will collaboratively pursue a wide array of research grant opportunities from government, industry and non-profit organizations to accelerate development of promising research and technologies that can be licensed out and/or spun out into the University's new innovation center.

This new partnership between The Hamner Institutes and the University will also draw upon extensive resources available at the state's other academic institutions and the North Carolina Biotechnology Center, which supports statewide faculty recruitment, scientific education, economic development and technology development.


"At Carolina, we are committed to making sure that the discoveries of basic science benefit people," said UNC-Chapel Hill Chancellor James Moeser. "This partnership with the Hamner Institutes will help us accelerate the development of valuable new drugs, treatments and technologies that improve health and also yield new economic opportunities for North Carolinians."

"We are extremely pleased and honored to be joining with one of the world's leading research universities to create a unique integrative model for translating basic science research into new medicines," said Dr. William Greenlee, President and CEO of The Hamner Institutes for Health Sciences. "This partnership also will foster new alliances between academe, industry and government regulatory agencies to advance public health research, education and scientifically informed policies."

About The Hamner Institutes for Health Sciences:

Strategically located on a 56-acre campus in North Carolina's Research Triangle Park, The Hamner Institutes for Health Sciences is a cross-disciplinary nonprofit organization that acts as a catalyst to facilitate scientific collaborations -- both locally and internationally -- between academia, the private sector and government. For more than 30 years, Hamner scientists have been recognized for their public-policy leadership and research advances in fields such as risk assessment, dose-response modeling and inhalation drug delivery. For more information, visit or call (919) 558-1200.


Patty Briguglio


SOURCE The Hamner Institutes for Health Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. National Institutes of Health Awards $25.5M Contract to SRA
2. Biotherm Announces a Unique Dermobiotic Three-Step Anti-Cellulite Slimming Treatment
3. The Lustgarten Foundation for Pancreatic Cancer Research Launches New Public Service Announcement Featuring Last Lecturer Dr. Randy Pausch
4. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
5. BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress
6. ARUP Laboratories CEO and Co-Founder Announces Retirement
7. First Quarter 2008 Financial Results Announcement and Teleconference
8. Gene Network Sciences Names New CSO and Announces New Scientific Advisory Board
9. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
10. Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement
11. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: ) ... provide their customers enhanced security to access and ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):